Top News and Analysis for R&D and Executive Leaders

 

Week of 7.2.08

tbar.gif

Best Practices
Click here to
submit entries

Neil W Gibson of OSI Pharmaceuticals

Jeffrey Settleman,  Harvard Medical School and MGH Cancer Center

David Bailey of Chemoventures

N Claude Cohen of Synergix

-View All Webcasts

 

 

  
     

 

  

Business

Buffett Bolsters GSK, Sanofi-Aventis

February 15, 2008--Warren Buffett’s investment company has bought 1.51 million American depositary receipts (ADRs) in GlaxoSmithKline, valued at $76.1 million; also 3.6 million ADRs in Sanofi-Aventis, valued at $162.5 million. Buffett’s firm also has a $4.1 billion stake in Johnson & Johnson. Forbes.com

 
 

Genstruct: Patience, Persistence, and Payoff 
By John Russell
Finding the right business model for systems biology (SB) technology providers has been challenging — that’s hardly a new theme in biotech.

Click here

 


PharmaWeek is subject to the terms and conditions of use. 
Please read the important legal notices and disclaimers contained in these terms and conditions of use.

Copyright 2005  Cambridge Healthtech Institute  |  250 First Avenue  |   Suite 300   |   Needham,  MA  02494
Phone: 781-972-5400  |   Fax: 781-972-5425